AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced that the Company has filed a provisional patent application for the use of ketamine and peptides to treat
Alterity Therapeutics Limited ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company") has received guidance from the European Medicines Agency (EMA) regarding key aspects of the